Literature DB >> 22925496

Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.

Filip Y De Vos1, Johanna M Gijtenbeek, Chantal P Bleeker-Rovers, Carla M van Herpen.   

Abstract

High-grade glioma patients receiving concomitant chemoradiotherapy with temozolomide 75mg/m(2) during six to seven weeks or dose-dense temozolomide regimens especially in combination with chronic use of corticosteroids have a high risk for developing Pneumocystis jirovecii pneumonia. In this review, we define risk groups and propose a guideline for prophylaxis using risk stratification.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925496     DOI: 10.1016/j.critrevonc.2012.08.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.

Authors:  Shiyuan Anabeth Liu; Timothy Sullivan; Clare Bryce; Amy M Chan; Salvatore Cilmi
Journal:  BMJ Case Rep       Date:  2019-05-31

Review 2.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

3.  Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy.

Authors:  Seth A Climans; Warren P Mason; Eva Grunfeld; Kelvin Chan
Journal:  J Neurooncol       Date:  2022-08-06       Impact factor: 4.506

4.  Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.

Authors:  Seth A Climans; Eva Grunfeld; Warren P Mason; Kelvin K W Chan
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

5.  Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.

Authors:  Alexander J Neuwelt; Tam M Nguyen; Rongwei Fu; Joseph Bubalo; Rose Marie Tyson; Cynthia Lacy; Seymur Gahramanov; Morad Nasseri; Penelope D Barnes; Edward A Neuwelt
Journal:  CNS Oncol       Date:  2014-07

Review 6.  What next for newly diagnosed glioblastoma?

Authors:  Evidio Domingo-Musibay; Evanthia Galanis
Journal:  Future Oncol       Date:  2015-11-12       Impact factor: 3.404

7.  Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.

Authors:  Reena P Thomas; Lawrence Recht; Seema Nagpal
Journal:  Clin Pharmacol       Date:  2012-12-27

8.  Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT'AIDS Study.

Authors:  Nathalie Pansu; Vincent Le Moing; Isabelle Poizot-Martin; Véronique Joly; Clotilde Allavena; Laurent Hocqueloux; Claudine Duvivier; Jeremy Lourenco; Thomas Jovelin; Jacques Reynes; Alain Makinson
Journal:  Open Forum Infect Dis       Date:  2022-03-02       Impact factor: 3.835

9.  Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists.

Authors:  Nebojša Skorupan; Surabhi Ranjan; Seema Mehta; Olga Yankulina; Nathan Nenortas; Stuart Grossman; Xiaobu Ye; Matthias Holdhoff
Journal:  Neurooncol Pract       Date:  2018-11-29

10.  Severe pneumocystis jiroveci pneumonia in a patient on temozolomide therapy: A case report and review of literature.

Authors:  Babar Ahmad Khan; Sania Khan; Benjamin White; Ambika Eranki
Journal:  Respir Med Case Rep       Date:  2017-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.